A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

pharmaphorum is your source for news and analysis to stay on top of happenings in the world of pharma. Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

This time last year, Croda Pharma and Botanical Solution Inc (BSI) announced that they’d entered into a strategic collaboration agreement to support the sustainable sourcing of pharmaceutical ...

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating its position as the ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD. J&J’s $2 billion play for ...

From streamlining clinical trials to evaluating drug repurposing possibilities for new patient populations and addressing critical supply chain challenges, 2024 will be the year artificial ...